PATENT CLAIM ANALYSIS

Application Number: 16109198
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "422000"]

Abstract:
Disclosed are biocompatible, biodegradable, implantable devices for the controlled release of bioactive molecules. In particular embodiments, nanotechnology-based tunable implants are disclosed for 1) localized delivery of analgesics to treat postoperative pain; 2) sustained delivery of growth factors to promote vascularization; and 3) directing tissue regeneration, including the self-direction of autologous stem cells for organ remodeling.

Claim (Index 33):
The method of  claim 31 , wherein the at least one therapeutic agent is selected from the group consisting of bupivacaine, novacaine, lidocaine, and combinations thereof, in an amount effective to provide localized analgesia, or the alleviation of post-surgical pain.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 96.0
- Lexical Diversity: 1.32
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14967165', '13708888', '14266729', '11560352', '15270324']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7435118125140393
- 35 USC 102 Novelty (BERT): 0.4940007146553501
- Combined Prediction Score: 0.7185607027281704
- Mean Citation Score: 163.054886
- Max Citation Score: 170.39989
- Similarity Product: 103.60220553575996

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test